Noa Biran, MD

Noa Biran, MD, highlighted the real-world use of the SKY92 gene expression profiling assay for multiple myeloma risk stratification.

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Noa Biran, MD, discusses the investigation of belantamab mafodotin plus bortezomib and dexamethasone in multiple myeloma.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss ongoing clinical trials in multiple myeloma.

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Noa Biran, MD, physician, discusses elotuzumab (Empliciti) as post-autologous stem cell transplant consolidation in patients with high-risk myeloma.

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Noa Biran, MD, discusses new agents and combinations being studied for relapsed multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.